Compare Adaptive Biotechnologies Corp (ADPT) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NIO Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while NIO Inc. trades at $4.57 (market cap $11.59B). The key difference: NIO Inc. is far larger — about 2.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | NIO | |
|---|---|---|
Market Cap | $4.04B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $7.89 |
52-Week Low | $12.30 | $4.44 |
Enterprise Value | $4.10B | $10.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
NIO trades at $4.82, up 1.69% today, showing recent volatility amid mixed market signals. The company reported July 2026 deliveries growth and has beaten earnings expectations for three consecutive quarters, though it remains unprofitable with a net income margin of -9.09%. Technical indicators show neutral momentum with RSI at neutral levels, while analyst sentiment leans bullish with 54% buy ratings.
NIO presents a high-risk growth opportunity with improving revenue trends but persistent losses. The stock offers potential upside if profitability improves, but faces significant execution risks in the competitive EV market. Investors should weigh strong delivery growth against cash burn and negative equity returns before considering position entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
